Related Experiment Videos
[Alpha blockaders--first or second line antihypertensive agents?]
P Lund-Johansen1, I Hjermann, B M Iversen
1Hjerteavdelingen, Haukeland sykehus, Bergen.
Insights
Alpha-receptor blockers effectively lower blood pressure by targeting alpha 1-receptors without impacting heart function. These medications also improve lipid profiles and do not affect electrolytes, glucose, or uric acid metabolism.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
Background:
- Alpha-receptor blockers are a class of drugs used to treat hypertension.
- Their mechanism involves blocking alpha 1-receptors in vascular smooth muscle.
Purpose of the Study:
- To summarize the effects of alpha-receptor blockers on blood pressure and cardiovascular health.
- To highlight their metabolic and pulmonary effects.
- To outline appropriate clinical use and contraindications.
Main Methods:
- Review of existing studies on alpha-receptor blockers.
- Analysis of their impact on blood pressure, lipid profiles, and metabolic parameters.
- Evaluation of safety and efficacy in different patient populations.
Main Results:
- Alpha-receptor blockers reduce blood pressure by blocking alpha 1-receptors, without impairing cardiac function.
- They improve lipid profiles by reducing triglycerides and increasing HDL/LDL cholesterol ratio.
- No adverse effects on electrolytes, glucose, uric acid, or pulmonary function were observed.
Conclusions:
- Alpha-receptor blockers are a safe and effective first-line antihypertensive treatment when used appropriately.
- Consideration of potential side effects like transient tachycardia is necessary.
- Contraindicated in coronary heart disease patients not on beta-blockade.
Abstract:
Alpha-receptor blockers reduce blood pressure by blocking of the alpha 1-receptors in the smooth muscle cells in the arteriolar walls. The heart pump function is not disturbed. Most studies have shown that the alpha-receptor blockers induce a reduction in plasma-triglycerides and an increase in the ratio between HDL- and LDL-cholesterol. They do not interfere with the metabolism of electrolytes, glucose or uric acid and have no negative effect on pulmonary function. Although long-term use does not induce a permanent increase in heart rate, some patients respond to initial therapy with faster heart rate and palpitations. The alpha-receptor blockers should not be used in patients with coronary heart disease if the patient is not on chronic beta-blockade. When these precautions are followed, the alpha-blockers can be used as first-line treatment--just like ACE-inhibitors and calcium-antagonists.